Chris Dunk - May 28, 2021 Form 3 Insider Report for Immune Therapeutics, Inc. (IMUN)

Role
Member of 10% owner group
Signature
/s/ Chris Dunk
Stock symbol
IMUN
Transactions as of
May 28, 2021
Transactions value $
$0
Form type
3
Date filed
6/7/2021, 06:29 AM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IMUN Common Stock 2.15K May 28, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMUN Warrants (Right to Buy) May 28, 2021 Common Stock 5K $5.00 Direct
holding IMUN Warrants (Right to Buy) May 28, 2021 Common Stock 30K $5.00 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 According to the Annual Report on Form 10-K filed on April 15, 2021 (the "Form 10-K") by the issuer, Immune Therapeutics, Inc. (the "Company"), a reverse stock split of the Company's issued and outstanding, but not authorized, common stock at a ratio of 1,000-to-1 (the "Reverse Split") was approved by the Company's shareholders. The Reverse Split is currently pending approval by the Financial Industry Regulatory Authority, Inc. The information contained in the Form 10-K relating to the shares of Common Stock outstanding and beneficially owned is based on the implementation of the Reverse Split. The information presented herein is likewise based on the implementation of the Reverse Split. The beneficial ownership information presented in this Form 3 is otherwise based on the beneficial ownership of the Reporting Persons as of the date of the event requiring filing of this Form 3.